|
subsections menu :
Contacts
|
Content :
Press releases
Paris, France, March 7, 2008 Sanofi-aventis Board of DirectorsThe Board of Directors’ meeting held on February 11, 2008 discussed the reappointment of thirteen members of the Board of Directors whose terms of office expire at the end of the General Shareholders’ meeting to be held on May 14, 2008. The Board of Directors decided to submit at the General Shareholders’ meeting the reappointment of Mssr. Jean-François Dehecq, Jean-Marc Bruel, Robert Castaigne, Thierry Desmarest, Jean-René Fourtou, Igor Landau, Christian Mulliez, Lindsay Owen-Jones and Klaus Pohle. Four Directors are not seeking reappointment (Mssr. René Barbier de La Serre, Jürgen Dormann, Hubert Markl and Bruno Weymuller). The Board of Directors proposes to the General Shareholders’ meeting the appointment of four new directors: Mrs. Claudie Haigneré, Mr. Uwe Bicker, Mr. Patrick de la Chevardière and Mr. Gunter Thielen. Mrs. Claudie Haigneré is a certified rheumatologist and holds a doctorate in science specialized in neurosciences. She participated in several spatial missions (Station MIR in 1996, International Space Station in 2001). She also served as Ministre Français Délégué à la Recherche et aux Nouvelles Technologies (2002-2004) and as Ministre Français Délégué aux Affaires Européennes (2004-2005). Since November 2005, Mrs. Claudie Haigneré has been an Advisor of the Director General of the European Space Agency (ESA). Mr. Uwe Bicker is a physician and holds a doctorate in chemistry. He is a Professor at the Medical Faculty of the Heidelberg University and a Doctor honoris causa at the Klausenburg University. He has been a member of the Board of Bertelsmann Stiftung (Foundation Bertelsmann) since January 2008. Mr. Patrick de la Chevardière is a graduate of the Ecole Centrale de Paris. Since September 2003, he has served as Deputy Chief Financial Officer of Total. Mr. Gunter Thielen has a doctorate in physical chemistry and a degree in economics and industrial engineering. Since January 2008, he has served as Chairman of the Supervisory Board of Bertelsmann AG, Gütersloh and Chairman of the Executive Board of Bertelsmann Stiftung (Foundation Bertelsmann). The Board, in accordance with the by-laws’ provisions on rotating directorships, proposes to the General Shareholders’ meeting that the duration of the terms be staggered so that, beginning in 2010, one third of the Board will be renewed each year. The new Board of Directors would comprise the following members (year term ends):
About sanofi-aventisSanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|
Press releases and press packs are intended to journalists, investors and shareholders.